AbbVie Inc. (ABBV)

業務介紹

AbbVie Inc.是一家在全球範圍內進行藥物的發現、研發、製造和銷售的公司。該公司提供HUMIRA，一種用於自體免疫和腸道貝賽特病的注射治療；SKYRIZI，用於治療成年人中度至重度銀屑病的藥物；RINVOQ，一種JAK抑制劑，用於治療成年患者中度至重度活躍性類風濕性關節炎；IMBRUVICA，用於治療慢性淋巴細胞白血病（CLL）、小淋巴細胞淋巴瘤（SLL）的成年患者，以及VENCLEXTA，一種BCL-2抑制劑，用於治療慢性淋巴細胞白血病（CLL）或小淋巴細胞淋巴瘤（SLL）的成年患者；以及MAVYRET，用於治療慢性HCV基因型1-6感染的患者。此外，該公司還提供CREON，一種胰酶治療劑，用於外分泌性胰腺功能不全；Synthroid，用於治療甲狀腺功能低下症；Linzess/Constella，用於治療伴有便秘的腸易激綜合徵和慢性特發性便秘；Lupron，用於姑息治療晚期前列腺癌、子宮內膜異位症和中樞性性早熟，以及由子宮肌瘤引起的貧血患者；以及Botox治療劑。此外，該公司還提供ORILISSA，一種非肽小分子促性腺激素釋放激素拮抗劑，用於治療中度至重度子宮內膜異位症疼痛的女性；Duopa和Duodopa，一種左旋多巴-卡比多巴腸道凝膠，用於治療帕金森病；Lumigan/Ganfort，一種比馬前列素眼用溶液，用於降低開角型青光眼（OAG）或眼壓增高患者的眼內壓；Ubrelvy，用於治療成年人的偏頭痛（伴有或不伴有先兆）；Alphagan/Combigan，一種α-腎上腺素受體激動劑，用於降低開角型青光眼患者的眼內壓；以及Restasis，一種鈣調蛋白酶抑制劑免疫抑制劑，用於增加淚液分泌，以及其他眼部護理產品。AbbVie Inc.與Dragonfly Therapeutics, Inc.進行研究合作。該公司成立於2012年，總部位於伊利諾伊州北芝加哥。

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

公司網址

https://www.abbvie.com